Scarica l'app Stockscreener
0.7363
11.29%
-0.0937
Dopo l'orario di chiusura:
.78
0.0437
+5.94%
Precedente Chiudi:
$0.83
Aprire:
$0.7998
Volume 24 ore:
1.44M
Relative Volume:
1.54
Capitalizzazione di mercato:
$43.24M
Reddito:
-
Utile/perdita netta:
$-123.46M
Rapporto P/E:
-0.2843
EPS:
-2.59
Flusso di cassa netto:
$-104.11M
1 W Prestazione:
-27.81%
1M Prestazione:
+1.97%
6M Prestazione:
+133.67%
1 anno Prestazione:
-62.43%
Intervallo 1D:
$0.6597
$0.8609
Intervallo di 1 settimana:
$0.6597
$1.06
Portata 52W:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Nome
Bioatla Inc
Settore
Industria
Telefono
858-558-0708
Indirizzo
11085 TORREYANA ROAD, SAN DIEGO
Confronta BCAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.7363 | 47.03M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-13 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-05-05 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-06-28 | Iniziato | ROTH Capital | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | BTIG Research | Buy |
| 2021-01-11 | Iniziato | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | JP Morgan | Overweight |
| 2021-01-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Bioatla Inc Borsa (BCAB) Ultime notizie
Will BioAtla Inc. continue its uptrendWeekly Gains Summary & Safe Capital Allocation Plans - newser.com
Chart overlay techniques for tracking BioAtla Inc.July 2025 Sector Moves & AI Enhanced Trading Alerts - newser.com
How supply chain issues affect BioAtla Inc. stockDip Buying & Verified Swing Trading Watchlist - newser.com
Will BioAtla Inc. stock keep outperforming rivalsPortfolio Performance Report & Daily Profit Focused Stock Screening - newser.com
Why BioAtla Inc. stock is favored by top institutions2025 Technical Overview & Stepwise Trade Execution Plans - newser.com
BioAtla (NASDAQ:BCAB) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
Why BioAtla Inc. stock is rated strong buyStop Loss & Short-Term High Return Strategies - newser.com
Published on: 2025-10-14 04:44:51 - newser.com
Understanding BioAtla Inc.’s price movementWeekly Earnings Recap & AI Driven Stock Price Forecasts - newser.com
Strategies to average down on BioAtla Inc.2025 Support & Resistance & Verified Swing Trading Watchlists - newser.com
How to use a screener to detect BioAtla Inc. breakoutsWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
Is BioAtla Inc. reversing from oversold territoryJuly 2025 Recap & Verified Swing Trading Watchlist - newser.com
Real time breakdown of BioAtla Inc. stock performancePrice Action & Low Drawdown Momentum Ideas - newser.com
Order flow analysis tools used on BioAtla Inc.Quarterly Profit Report & Weekly High Conviction Ideas - newser.com
How institutional ownership impacts BioAtla Inc. stockJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
Technical signs of recovery in BioAtla Inc.Portfolio Performance Report & Low Drawdown Investment Strategies - newser.com
What’s next for BioAtla Inc. stock priceEarnings Miss & Long-Term Growth Plans - newser.com
Applying Elliott Wave Theory to BioAtla Inc.Bull Run & Weekly High Momentum Picks - newser.com
Why BioAtla Inc. stock could outperform in 2025Risk Management & Expert Approved Momentum Trade Ideas - newser.com
Will BioAtla Inc. stock recover after recent dropJuly 2025 Drop Watch & AI Optimized Trading Strategy Guides - newser.com
Can technical indicators confirm BioAtla Inc.’s reversalWeekly Stock Recap & High Return Stock Watch Alerts - newser.com
Historical volatility pattern of BioAtla Inc. visualizedMarket Sentiment Review & Fast Gain Stock Trading Tips - newser.com
Should you wait for a breakout in BioAtla Inc.Bond Market & Community Shared Stock Ideas - newser.com
Can momentum traders help lift BioAtla Inc.2025 Volume Leaders & Growth Focused Entry Reports - newser.com
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - GlobeNewswire
BioAtla, Inc. to Present Clinical Data on AXL-Targeting ADC Mecbotamab Vedotin at SITC 2025 Annual Meeting - Quiver Quantitative
Median OS 21.5 months: BioAtla presents mecbotamab vedotin data in 44 sarcoma patients at SITC - Stock Titan
Detecting price anomalies in BioAtla Inc. with AIWeekly Trading Summary & Risk Managed Investment Strategies - newser.com
Real time alert setup for BioAtla Inc. performanceJuly 2025 Reactions & Technical Entry and Exit Alerts - newser.com
Bioatla Inc Azioni (BCAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):